Skip to main content
Erschienen in: Clinical Pharmacokinetics 9/2020

22.03.2020 | Original Research Article

An Extension of Janmahasatian’s Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities

verfasst von: Jaydeep Sinha, Hesham S. Al-Sallami, Stephen B. Duffull

Erschienen in: Clinical Pharmacokinetics | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Fat-free mass (FFM)-based dose scaling is increasingly being adopted in clinical pharmacology. Given the complexities with the measurement of FFM in clinical practice, choosing an appropriate equation for FFM is critical for accurate dose scaling. Janmahasatian’s FFM model (FFMJan) has largely remained the preferred choice because of its mechanistic basis and good predictive properties. This model was, however, developed from a largely European cohort and has been shown to give biased predictions of FFM in Indian people.

Objective

The objective of this work was to derive an extended version of the FFMJan model (FFMExt) that accounts for the variation in body composition due to ethnicity, and to demonstrate its application by developing an extended FFM model in an Indian population (FFMExt,Ind).

Methods

The fundamental assumption of FFMJan model development was a linear relationship between bioimpedance and body mass index. In this extension to Janmahasatian’s work, this assumption was extended to allow for potential non-linear relationships. While the original ZJan model parameters were kept fixed, a set of body composition-related parameters \(\varPsi \{ \psi_{1} , \;\psi_{2} , \;\psi_{3} \}\) were incorporated, where \(\psi_{1}\) and \(\psi_{2}\) were the ethnicity factors to the intercept and the linear coefficient, respectively, and \(\psi_{3}\) a non-linear exponent. The model was then applied to data arising from a south Indian population and the \(\varPsi\) parameters were estimated by standard non-linear regression. The data were generated from a reference model for FFM for the Indian population, which was known to provide unbiased estimates for this population.

Results

The parameter estimates (%RSE) of the final FFMExt,Ind model were \(\psi_{1} = 0\) (fixed), \(\psi_{2} = 0.77\) (3.2%) for male patients, 0.70 (3.3%) for female patients, and \(\psi_{3} = 0.72\) (12.4%). The final model predictions were in good agreement with the reference model predictions.

Conclusions

An FFMExt model has been achieved by extending the original FFMJan model assumptions to account for inter-ethnic differences in body composition. The extended model can be applied to any ethnic population by estimating a set of body composition-related parameters \(\varPsi\). This can be performed using bioimpedance data without the need for formal FFM measurements.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siri WE. Body composition from fluid spaces and density: analysis of methods. In: Josef Brozek AH, editor. Techniques for measuring body composition. Washington, DC: National Academy of Sciences-National Research Council; 1961. p. 223–44. Siri WE. Body composition from fluid spaces and density: analysis of methods. In: Josef Brozek AH, editor. Techniques for measuring body composition. Washington, DC: National Academy of Sciences-National Research Council; 1961. p. 223–44.
2.
Zurück zum Zitat Sinha J, Duffull SB, Al-Sallami HS. A review of the methods and associated mathematical models used in the measurement of fat-free mass. Clin Pharmacokinet. 2018;57(7):781–95.CrossRef Sinha J, Duffull SB, Al-Sallami HS. A review of the methods and associated mathematical models used in the measurement of fat-free mass. Clin Pharmacokinet. 2018;57(7):781–95.CrossRef
3.
Zurück zum Zitat Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119–33.CrossRef Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119–33.CrossRef
4.
Zurück zum Zitat De Baerdemaeker LE, Mortier EP, Struys MM. Pharmacokinetics in obese patients. Contin Educ Anaesth Crit Care Pain. 2004;4(5):152–5.CrossRef De Baerdemaeker LE, Mortier EP, Struys MM. Pharmacokinetics in obese patients. Contin Educ Anaesth Crit Care Pain. 2004;4(5):152–5.CrossRef
5.
Zurück zum Zitat Han P, Duffull S, Kirkpatrick C, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505–8.CrossRef Han P, Duffull S, Kirkpatrick C, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505–8.CrossRef
6.
Zurück zum Zitat Eleveld DJ, Proost JH, Absalom AR, Struys MM. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet. 2011;50(11):751–3.CrossRef Eleveld DJ, Proost JH, Absalom AR, Struys MM. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet. 2011;50(11):751–3.CrossRef
7.
Zurück zum Zitat Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol. 2011;25(1):27–36.CrossRef Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol. 2011;25(1):27–36.CrossRef
8.
Zurück zum Zitat De Baerdemaeker LEC, Van Limmen JGM, Van Nieuwenhove Y. How should obesity be measured and how should anesthetic drug dosage be calculated? In: Leykin Y, Brodsky JB, editors. Controversies in the anesthetic management of the obese surgical patient. Milan: Springer; 2013. p. 15–30.CrossRef De Baerdemaeker LEC, Van Limmen JGM, Van Nieuwenhove Y. How should obesity be measured and how should anesthetic drug dosage be calculated? In: Leykin Y, Brodsky JB, editors. Controversies in the anesthetic management of the obese surgical patient. Milan: Springer; 2013. p. 15–30.CrossRef
9.
Zurück zum Zitat Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg. 2011;113(1):57–62.CrossRef Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg. 2011;113(1):57–62.CrossRef
10.
Zurück zum Zitat Cortinez LI, Anderson BJ, Holford NH, Puga V, de la Fuente N, Auad H, et al. Dexmedetomidine pharmacokinetics in the obese. Eur J Clin Pharmacol. 2015;71(12):1501–8.CrossRef Cortinez LI, Anderson BJ, Holford NH, Puga V, de la Fuente N, Auad H, et al. Dexmedetomidine pharmacokinetics in the obese. Eur J Clin Pharmacol. 2015;71(12):1501–8.CrossRef
11.
Zurück zum Zitat La Colla L, Albertin A, La Colla G, Porta A, Aldegheri G, Di Candia D, et al. Predictive performance of the ‘Minto’remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clin Pharmacokinet. 2010;49(2):131–9.CrossRef La Colla L, Albertin A, La Colla G, Porta A, Aldegheri G, Di Candia D, et al. Predictive performance of the ‘Minto’remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clin Pharmacokinet. 2010;49(2):131–9.CrossRef
12.
Zurück zum Zitat Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.CrossRef Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.CrossRef
13.
Zurück zum Zitat Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB. Prediction of fat-free mass in children. Clin Pharmacokinet. 2015;54(11):1169–78.CrossRef Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB. Prediction of fat-free mass in children. Clin Pharmacokinet. 2015;54(11):1169–78.CrossRef
14.
Zurück zum Zitat Rush EC, Plank LD, Laulu MS, Robinson SM. Prediction of percentage body fat from anthropometric measurements: comparison of New Zealand European and Polynesian young women. Am J Clin Nutr. 1997;66(1):2–7.CrossRef Rush EC, Plank LD, Laulu MS, Robinson SM. Prediction of percentage body fat from anthropometric measurements: comparison of New Zealand European and Polynesian young women. Am J Clin Nutr. 1997;66(1):2–7.CrossRef
15.
Zurück zum Zitat Rush E, Plank L, Chandu V, Laulu M, Simmons D, Swinburn B, et al. Body size, body composition, and fat distribution: a comparison of young New Zealand men of European, Pacific Island, and Asian Indian ethnicities. N Z Med J. 2004;117(1207):U1203.PubMed Rush E, Plank L, Chandu V, Laulu M, Simmons D, Swinburn B, et al. Body size, body composition, and fat distribution: a comparison of young New Zealand men of European, Pacific Island, and Asian Indian ethnicities. N Z Med J. 2004;117(1207):U1203.PubMed
16.
Zurück zum Zitat Rush EC, Freitas I, Plank LD. Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults. Br J Nutr. 2009;102(4):632–41.CrossRef Rush EC, Freitas I, Plank LD. Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults. Br J Nutr. 2009;102(4):632–41.CrossRef
17.
Zurück zum Zitat Swinburn B, Ley S, Carmichael H, Plank L. Body size and composition in Polynesians. Int J Obes. 1999;23(11):1178.CrossRef Swinburn B, Ley S, Carmichael H, Plank L. Body size and composition in Polynesians. Int J Obes. 1999;23(11):1178.CrossRef
18.
Zurück zum Zitat Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002;3(3):141–6.CrossRef Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002;3(3):141–6.CrossRef
19.
Zurück zum Zitat Srigiripura CV, Urooj A, Krishnarao CS, Anand MP. Validation of fat-free mass estimation using prediction equations in male patients with chronic obstructive pulmonary disease. Int J Nutr Pharmacol Neurol Dis. 2017;7(4):94–100.CrossRef Srigiripura CV, Urooj A, Krishnarao CS, Anand MP. Validation of fat-free mass estimation using prediction equations in male patients with chronic obstructive pulmonary disease. Int J Nutr Pharmacol Neurol Dis. 2017;7(4):94–100.CrossRef
20.
Zurück zum Zitat Kulkarni B, Kuper H, Taylor A, Wells JC, Radhakrishna KV, Kinra S, et al. Development and validation of anthropometric prediction equations for estimation of lean body mass and appendicular lean soft tissue in Indian men and women. J Appl Physiol. 2013;115(8):1156–62.CrossRef Kulkarni B, Kuper H, Taylor A, Wells JC, Radhakrishna KV, Kinra S, et al. Development and validation of anthropometric prediction equations for estimation of lean body mass and appendicular lean soft tissue in Indian men and women. J Appl Physiol. 2013;115(8):1156–62.CrossRef
21.
Zurück zum Zitat McLeay S, Morrish G, Ponnuswamy T, Devanand B, Ramanathan M, Venkatakrishnan L, et al. Noninvasive quantification of hepatic steatosis: relationship between obesity status and liver fat content. Open Obes J. 2014;6(1):16–24.CrossRef McLeay S, Morrish G, Ponnuswamy T, Devanand B, Ramanathan M, Venkatakrishnan L, et al. Noninvasive quantification of hepatic steatosis: relationship between obesity status and liver fat content. Open Obes J. 2014;6(1):16–24.CrossRef
22.
Zurück zum Zitat Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716–23.CrossRef Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716–23.CrossRef
Metadaten
Titel
An Extension of Janmahasatian’s Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities
verfasst von
Jaydeep Sinha
Hesham S. Al-Sallami
Stephen B. Duffull
Publikationsdatum
22.03.2020
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 9/2020
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-020-00883-1

Weitere Artikel der Ausgabe 9/2020

Clinical Pharmacokinetics 9/2020 Zur Ausgabe